(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Avangrid Announces Major Contribution to Yale University for Clean Energy Research, Cara Therapeutics Reports Better-than-Expected Q1 Results, Kodiak Sciences and Fortress Biotech Slightly Miss Estimates

  • May 15th, 2023
  • 474 views

Avangrid, Inc. (NYSE: AGR) has announced a significant contribution to Yale University aimed at supporting innovative research projects that advance the clean energy transition. The funding from Avangrid will specifically target research initiatives focused on solar energy, battery storage, electric vehicles (EVs), and other related topics related to clean energy transition.

After-hours trading for $AGR shows the stock at $40.55, reflecting an increase of $0.60 (+1.50%).

Cara Therapeutics, Inc. (Nasdaq: CARA) has reported a loss of $0.49 per share for the first quarter, better than the consensus estimate of a loss of $0.52 per share.

After-hours trading for $CARA indicates the stock at $4.61, experiencing a notable increase of $0.46 (+11.08%).

Kodiak Sciences Inc. (Nasdaq: KOD) has reported a loss of $1.35 per share for the first quarter 2023, bit worse than the consensus estimate of a loss of $1.33 per share.

On Monday, $KOD closed at $5.27, demonstrating a substantial increase of $0.59 (+12.61%).

Fortress Biotech, Inc. (Nasdaq: FBIO) has reported a loss of $0.21 per share for Q1 2023, slightly worse than the consensus estimate of a loss of $0.20 per share.

On Monday, $FBIO closed at $0.70, showing a slight decrease of $0.01 (-1.39%).

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13